Published in J Virol on June 27, 2007
Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol (2009) 1.10
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica (2009) 1.08
Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J Virol (2012) 0.99
Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome. J Virol (2011) 0.95
Histone deacetylases in viral infections. Clin Epigenetics (2010) 0.93
Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression. Brain Behav Immun (2010) 0.91
Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. Adv Virol (2012) 0.89
Tousled-like kinases modulate reactivation of gammaherpesviruses from latency. Cell Host Microbe (2013) 0.89
Proteomic analysis reveals selective impediment of neuronal remodeling upon Borna disease virus infection. J Virol (2008) 0.88
Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. J Virol (2011) 0.87
Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. J Virol (2009) 0.86
Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus. J Biol Chem (2013) 0.85
A locus encompassing the Epstein-Barr virus bglf4 kinase regulates expression of genes encoding viral structural proteins. PLoS Pathog (2014) 0.84
Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One (2008) 0.83
Leucine zipper domain is required for Kaposi sarcoma-associated herpesvirus (KSHV) K-bZIP protein to interact with histone deacetylase and is important for KSHV replication. J Biol Chem (2012) 0.83
Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids. J Virol (2014) 0.81
Epigenetics and Genetics of Viral Latency. Cell Host Microbe (2016) 0.79
A critical Sp1 element in the rhesus rhadinovirus (RRV) Rta promoter confers high-level activity that correlates with cellular permissivity for viral replication. Virology (2013) 0.79
Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus. MBio (2016) 0.76
Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol (1974) 26.25
Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science (2003) 12.90
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11
Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature (1978) 9.25
Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J Mol Biol (1984) 8.87
Characterization of the herpes simplex virion-associated factor responsible for the induction of alpha genes. J Virol (1983) 8.31
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Temporal regulation of herpes simplex virus type 1 transcription: location of transcripts on the viral genome. Cell (1977) 7.60
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol (1989) 5.67
Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology (1998) 5.43
A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol (1988) 5.28
Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol (1997) 4.45
Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol (1999) 4.20
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol (1987) 4.12
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol (1990) 4.09
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Nucleotide sequence and predicted amino acid sequence of a protein encoded in a small herpes simplex virus DNA fragment capable of trans-inducing alpha genes. Proc Natl Acad Sci U S A (1985) 3.75
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. J Virol (1987) 3.56
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol (2000) 3.50
Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer (1984) 3.49
Differential effects of translational inhibition in cis and in trans on the decay of the unstable yeast MFA2 mRNA. J Biol Chem (1994) 3.37
Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 3.33
Identification and characterization of an RNA molecule that copurifies with RNase P activity from HeLa cells. Genes Dev (1989) 3.16
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A (1996) 3.13
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol (1998) 2.84
Interactions of the Oct-1 POU subdomains with specific DNA sequences and with the HSV alpha-trans-activator protein. Genes Dev (1990) 2.80
An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes (1991) 2.77
Kaposi's sarcoma-associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein-Barr virus. J Virol (1999) 2.24
Structure of defective DNA molecules in Epstein-Barr virus preparations from P3HR-1 cells. J Virol (1984) 2.23
Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest (1997) 2.10
Characterization of a cellular factor which interacts functionally with Oct-1 in the assembly of a multicomponent transcription complex. Nucleic Acids Res (1990) 1.85
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst (2004) 1.80
Efficient transcription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1 genes requires protein synthesis. J Virol (1991) 1.79
Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. J Virol (2003) 1.70
Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol (2000) 1.64
Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription. J Virol (2006) 1.57
TPA-inducible Epstein-Barr virus genes in Raji cells and their regulation. Virology (1988) 1.56
Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J Virol (2001) 1.47
Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J Virol (1996) 1.47
Sequences of the Epstein-Barr Virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA. J Virol (1987) 1.45
Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J Virol (1989) 1.45
Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome. J Gen Virol (1996) 1.35
Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. Int J Cancer (1981) 1.32
Late gene expression from the Epstein-Barr virus BcLF1 and BFRF3 promoters does not require DNA replication in cis. J Virol (1997) 1.30
Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology (1991) 1.29
Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) encodes a homologue of the Epstein-Barr virus bZip protein EB1. J Gen Virol (1999) 1.26
Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J Virol (2006) 1.24
Strain variation in Epstein-Barr virus immediate early genes. Virology (1993) 1.23
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol (2002) 1.23
Lytic cycle gene regulation of Epstein-Barr virus. J Virol (2004) 1.21
An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol (2005) 1.19
Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C. J Virol (1991) 1.14
Transcriptions of the bacteriophage T4 template in vitro: separation of "delayed early" from "immediate early" transcription. Proc Natl Acad Sci U S A (1970) 1.11
Promoter sequences required for reactivation of Epstein-Barr virus from latency. J Virol (2002) 1.05
Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals. J Virol Methods (2006) 0.97
Spontaneous and cycloheximide-induced interleukin-10 mRNA expression in human mononuclear cells. Mol Immunol (1995) 0.87
Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated. Mol Cell Biochem (2001) 0.78
Cycloheximide increases proenkephalin and tyrosine hydroxylase gene expression in rat adrenal medulla. Mol Pharmacol (2000) 0.77
Expression and regulation of retinoid X receptors in B16 melanoma cells. J Cell Physiol (1995) 0.77
Protein synthesis inhibitor-mediated stability of adenomatous polyposis coli mRNA levels in HCT-116 colon cancer cells. Int J Oncol (1999) 0.76
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell (2012) 4.16
In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest (2009) 2.53
Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology (2013) 2.42
Open reading frame 50 protein of Kaposi's sarcoma-associated herpesvirus directly activates the viral PAN and K12 genes by binding to related response elements. J Virol (2002) 1.94
National health spending by medical condition, 1996-2005. Health Aff (Millwood) (2009) 1.92
MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med (2012) 1.82
Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol (2004) 1.81
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest (2012) 1.45
Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J Leukoc Biol (2009) 1.37
Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol (2003) 1.36
Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol (2002) 1.23
An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol (2005) 1.19
Two subclasses of Kaposi's sarcoma-associated herpesvirus lytic cycle promoters distinguished by open reading frame 50 mutant proteins that are deficient in binding to DNA. J Virol (2005) 1.14
Dendritic cells promote pancreatic viability in mice with acute pancreatitis. Gastroenterology (2011) 1.11
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation (2002) 1.11
Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors. J Virol (2009) 1.10
Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J Virol (2004) 1.09
Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver. Gastroenterology (2012) 1.08
National spending on cardiovascular disease, 1996-2008. J Am Coll Cardiol (2011) 1.07
EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev (2012) 1.07
Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J Virol (2005) 1.05
Disruption of Epstein-Barr virus latency in the absence of phosphorylation of ZEBRA by protein kinase C. J Virol (2002) 1.03
Autoregulation of DNA binding and protein stability of Kaposi's sarcoma-associated herpesvirus ORF50 protein. J Virol (2004) 1.02
Dendritic cell depletion exacerbates acetaminophen hepatotoxicity. Hepatology (2011) 1.00
In hepatic fibrosis, liver sinusoidal endothelial cells acquire enhanced immunogenicity. J Immunol (2010) 0.98
Abdominal wall necrotizing fasciitis from dislodged percutaneous endoscopic gastrostomy tubes: a case series. Am Surg (2004) 0.97
Cells lytically infected with Epstein-Barr virus are detected and separable by immunoglobulins from EBV-seropositive individuals. J Virol Methods (2006) 0.97
Effect of intra-operative fluid volume on peri-operative outcomes after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol (2011) 0.94
Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. J Clin Invest (2014) 0.94
Selective loss of c-Rel compromises dendritic cell activation of T lymphocytes. Cell Immunol (2003) 0.92
Role of fatty-acid synthesis in dendritic cell generation and function. J Immunol (2013) 0.92
Pancreatic cancer, inflammation, and microbiome. Cancer J (2014) 0.91
When the cost curve bent--pre-recession moderation in health care spending. N Engl J Med (2012) 0.91
Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol (2007) 0.89
The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits. HPB (Oxford) (2012) 0.88
Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J Clin Invest (2013) 0.88
Serum IgA antibodies to Epstein-Barr virus (EBV) early lytic antigens are present in primary EBV infection. J Infect Dis (2007) 0.87
Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. J Virol (2011) 0.87
Identification of constitutive phosphorylation sites on the Epstein-Barr virus ZEBRA protein. J Biol Chem (2005) 0.86
GM-CSF expands dendritic cells and their progenitors in mouse liver. Hepatology (2003) 0.86
Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus. J Virol (2009) 0.86
N-linked glycosylation is required for optimal function of Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6. J Exp Med (2004) 0.86
Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood (2007) 0.86
Phosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes. J Virol (2007) 0.86
Essential role of Rta in lytic DNA replication of Epstein-Barr virus. J Virol (2012) 0.85
A mobile functional region of Kaposi's sarcoma-associated herpesvirus ORF50 protein independently regulates DNA binding and protein abundance. J Virol (2008) 0.85
A subset of replication proteins enhances origin recognition and lytic replication by the Epstein-Barr virus ZEBRA protein. PLoS Pathog (2010) 0.84
Mutations of amino acids in the DNA-recognition domain of Epstein-Barr virus ZEBRA protein alter its sub-nuclear localization and affect formation of replication compartments. Virology (2008) 0.84
Immediate postlaparotomy small bowel obstruction: a 16-year retrospective analysis. Am Surg (2002) 0.84
Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZhet is not detectable in many human tissues in vivo. Intervirology (2009) 0.83
The Mobile Luminescence End-Station, MoLES: a new public facility at Daresbury Synchrotron. J Synchrotron Radiat (2003) 0.82
Efficient induction of nuclear aggresomes by specific single missense mutations in the DNA-binding domain of a viral AP-1 homolog. J Biol Chem (2011) 0.81
Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA. Proc Natl Acad Sci U S A (2013) 0.80
Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation. J Biol Chem (2009) 0.79
Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function. Virology (2009) 0.79
Thirty years into the genomics era: tumor viruses led the way. Yale J Biol Med (2006) 0.79
Pancreaticoureteral fistula following penetrating abdominal trauma. JOP (2007) 0.78
Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. J Community Health (2011) 0.78
Induction of TRIF- or MYD88-dependent pathways perturbs cell cycle regulation in pancreatic cancer. Cell Cycle (2013) 0.78
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report. J Gastrointest Cancer (2014) 0.77
Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048). J Mass Spectrom (2008) 0.77
Signaling via MYD88 in the pancreatic tumor microenvironment: A double-edged sword. Oncoimmunology (2013) 0.77
Team play in surgical education: a simulation-based study. J Surg Educ (2012) 0.77
Cost-effectiveness of cardiovascular disease spending. J Am Coll Cardiol (2012) 0.76
Serum IgA to Epstein-Barr virus early antigen-diffuse identifies Hodgkin's lymphoma. J Med Virol (2013) 0.75
Give American women a break. Congr Rec (Dly Ed) (1979) 0.75
Using models and data to support optimization of the Military Health System: a case study in an intensive care unit. Health Care Manag Sci (2004) 0.75
Body mass index and acetabular component position in total hip arthroplasty. ANZ J Surg (2012) 0.75
Evaluating the impact of partnerships to improve clinical quality. Jt Comm J Qual Patient Saf (2007) 0.75